Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GAVI Alliance Builds On Matching Fund On Heels Of Pfizer And GSK Vaccine Deal For Developing Countries

This article was originally published in PharmAsia News

Executive Summary

GAVI brings on new funding partners for immunization, supplementing expanded pneumococcal vaccine supply agreements with Pfizer and GSK.

You may also be interested in...



Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries

Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries

Southeast Asian Regulators Ramp Up Anti-Corruption, Bribery Enforcement Ahead of ASEAN Pact

Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.

St. Jude Introduces Allure Quadra To Hong Kong As It Seeks APAC Rebound For Pacemakers

The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC079392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel